Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.